Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO

The Journal of clinical endocrinology and metabolism1 Oct 1997Cited by 37 (Europe PMC)

PMID9329386DOI10.1210/jcem.82.10.4297PepBankPUB-09329386

Source link PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanNon-randomized trialSafety outcome
In GH-deficient men, MK‑677 was generally well tolerated.
In plain wordsIn growth hormone-deficient men, MK‑677 was generally well tolerated.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableGeneral tolerability
Study
n = 9
Outcome group
Adverse events · Whole body
Studied dose
10 or 50 mg once daily · oral · 4 daysAs given in this study (human).
Source sentences
Summary
The drug was generally well tolerated, with no significant changes from baseline in circulating concentrations of cortisol, PRL, and thyroid hormones.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938601
02HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 did not significantly change circulating cortisol from baseline.
In plain wordsIn growth hormone-deficient men, MK‑677 did not significantly change circulating cortisol from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCortisol concentration
Study
n = 9
Comparator
Baseline
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
10 or 50 mg once daily · oral · 4 daysAs given in this study (human).
Source sentences
Summary
The drug was generally well tolerated, with no significant changes from baseline in circulating concentrations of cortisol, PRL, and thyroid hormones.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938602
03HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 did not significantly change circulating PRL from baseline.
In plain wordsIn growth hormone-deficient men, MK‑677 did not significantly change circulating prolactin from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changePRL concentration
Study
n = 9
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oral · 4 daysAs given in this study (human).
Source sentences
Summary
The drug was generally well tolerated, with no significant changes from baseline in circulating concentrations of cortisol, PRL, and thyroid hormones.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938603
04HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 did not significantly change circulating thyroid hormones from baseline.
In plain wordsIn growth hormone-deficient men, MK‑677 did not significantly change circulating thyroid hormones from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeThyroid hormone concentrations
Study
n = 9
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oral · 4 daysAs given in this study (human).
Source sentences
Summary
The drug was generally well tolerated, with no significant changes from baseline in circulating concentrations of cortisol, PRL, and thyroid hormones.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938604
05HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 at 10 mg increased IGF-I by 52 +/- 20% from baseline.
In plain wordsIn growth hormone-deficient men, MK‑677 increased IGF-I from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-I at lower dose
Study
n = 9
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/day · oral · 4 daysAs given in this study (human).
Measurements
IGF-I change from baseline
52%
10 mg/day MK-677, geometric mean +/- intrasubject SE 20
IGF-I at baseline
65 micrograms/L
10 mg/day MK-677
IGF-I after treatment
99 micrograms/L
10 mg/day MK-677
p value for IGF-I at lower dose vs baseline
≤ 0.05 p
10 mg/day MK-677 vs baseline, after treatment
IGF-I baseline reported +/- uncertainty term
6 micrograms/L
10 mg/day MK-677, baseline
IGF-I after-treatment reported +/- uncertainty term
9 micrograms/L
10 mg/day MK-677, after treatment
Source sentences
Summary
After treatment with 10 mg MK-677, IGF-I concentrations increased 52 +/- 20% (65 +/- 6 to 99 +/- 9 micrograms/L, geometric mean +/- intrasubject SE, P < or = 0.05 vs. baseline)
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938605
06HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 at 10 mg increased mean GH by 79 +/- 19% from baseline.
In plain wordsIn growth hormone-deficient men, MK‑677 increased mean growth hormone from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseMean GH at lower dose
Study
n = 9
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/day · oral · 4 daysAs given in this study (human).
Measurements
24 h mean GH change from baseline
79%
10 mg/day MK-677, geometric mean +/- intrasubject SE 19
24 h mean GH at baseline
0.14 microgram/L
10 mg/day MK-677
24 h mean GH after treatment
0.26 microgram/L
10 mg/day MK-677
p value for Mean GH at lower dose vs baseline
≤ 0.05 p
10 mg/day MK-677 vs baseline, after treatment
24 h mean GH baseline reported +/- uncertainty term
0.01 microgram/L
10 mg/day MK-677, baseline
24 h mean GH after-treatment reported +/- uncertainty term
0.02 microgram/L
10 mg/day MK-677, after treatment
Source sentences
Summary
and 24 h mean GH concentrations increased 79 +/- 19% (0.14 +/- 0.01 to 0.26 +/- 0.02 microgram/L, P < or = 0.05 vs. baseline).
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938606
07HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 at 10 mg increased IGF binding protein-3 from baseline.
In plain wordsIn growth hormone-deficient men, MK‑677 increased IGF binding protein-3 from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF binding protein-3 at lower dose
Study
n = 9
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/day · oral · 4 daysAs given in this study (human).
Measurements
IGFBP-3 at baseline
1.2 micrograms/L
10 mg/day MK-677
IGFBP-3 after treatment
1.7 micrograms/L
10 mg/day MK-677
p value for IGF binding protein-3 at lower dose vs baseline
≤ 0.05 p
10 mg/day MK-677 vs baseline, after treatment
IGFBP-3 baseline reported +/- uncertainty term
0.1 micrograms/L
10 mg/day MK-677, baseline
IGFBP-3 after-treatment reported +/- uncertainty term
0.1 micrograms/L
10 mg/day MK-677, after treatment
Source sentences
Summary
Serum IGF binding protein-3 concentrations increased with both 10 mg (1.2 +/- 0.1 to 1.7 +/- 0.1 micrograms/L, P < or = 0.05) and 50 mg MK-677 (1.7 +/- 0.1 to 2.2 +/- 0.2 micrograms/L, P < or = 0.05).
5 context sentences(design, population, supporting numbers)
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Summary · context
Blood was collected every 20 min for 24 h before treatment and at the end of each period for GH measurement using an ultrasensitive assay.
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Report a problemFND-0932938609
08HumanNon-randomized trialMechanism
In GH-deficient men, the GH response to MK‑677 was positively related to baseline mean GH.
In plain wordsIn growth hormone-deficient men, the response to MK‑677 was linked to higher baseline growth hormone.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseGH response association with baseline GH
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/day · oral · 4 daysAs given in this study (human).
Measurements
Correlation of 24 h mean GH increase with baseline 24 h mean GH
0.81 r
10 mg/day MK-677
p value for association of 24-h mean GH increase with baseline 24-h mean GH
0.009 p
10 mg MK-677, linear regression
Source sentences
Summary
The GH response to MK-677 was greater in subjects who were the least GH/IGF-I deficient at baseline; by linear regression analysis the increase in 24-h mean GH concentration was positively related to both baseline 24-h mean GH concentration (r = 0.81, P = 0.009) and baseline IGF-I (r = 0.79, P = 0.01) for 10 mg MK-677.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938611
09HumanNon-randomized trialMechanism
In GH-deficient men, the GH response to MK‑677 was positively related to baseline IGF-I.
In plain wordsIn growth hormone-deficient men, the growth hormone response to MK‑677 was linked to higher baseline IGF-I.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseGH response association with baseline IGF-I
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/day · oral · 4 daysAs given in this study (human).
Measurements
Correlation of 24 h mean GH increase with baseline IGF-I
0.79 r
10 mg/day MK-677
p value for association of 24-h mean GH increase with baseline IGF-I
0.01 p
10 mg MK-677, linear regression
Source sentences
Summary
The GH response to MK-677 was greater in subjects who were the least GH/IGF-I deficient at baseline; by linear regression analysis the increase in 24-h mean GH concentration was positively related to both baseline 24-h mean GH concentration (r = 0.81, P = 0.009) and baseline IGF-I (r = 0.79, P = 0.01) for 10 mg MK-677.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938612
10HumanNon-randomized trialMechanism
In GH-deficient men, IGF-I responses to MK‑677 were not significantly related to baseline measurements.
In plain wordsIn growth hormone-deficient men, IGF-I responses to MK‑677 were not significantly linked to baseline measurements.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeIGF-I response association with baseline measurements
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oral · 4 daysAs given in this study (human).
Source sentences
Summary
IGF-I responses were not significantly related to any baseline measurement.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938613
11HumanNon-randomized trialEfficacy outcome
In GH-deficient men, fasting insulin increased significantly after MK‑677 treatment.
In plain wordsIn growth hormone-deficient men, fasting insulin increased significantly after MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseFasting insulin
Study
n = 9
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 4 daysAs given in this study (human).
Source sentences
Summary
Fasting and postprandial insulin and postprandial glucose increased significantly after MK-677 treatment, and the clinical significance of these changes will need to be assessed in longer term studies.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938614
12HumanNon-randomized trialEfficacy outcome
In GH-deficient men, postprandial insulin increased significantly after MK‑677 treatment.
In plain wordsIn growth hormone-deficient men, insulin after meals increased significantly after MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePostprandial insulin
Study
n = 9
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 4 daysAs given in this study (human).
Source sentences
Summary
Fasting and postprandial insulin and postprandial glucose increased significantly after MK-677 treatment, and the clinical significance of these changes will need to be assessed in longer term studies.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938615
13HumanNon-randomized trialEfficacy outcome
In GH-deficient men, postprandial glucose increased significantly after MK‑677 treatment.
In plain wordsIn growth hormone-deficient men, glucose after meals increased significantly after MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePostprandial glucose
Study
n = 9
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 4 daysAs given in this study (human).
Source sentences
Summary
Fasting and postprandial insulin and postprandial glucose increased significantly after MK-677 treatment, and the clinical significance of these changes will need to be assessed in longer term studies.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938616
14HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 at 50 mg increased IGF-I by 79 +/- 9% from baseline.
In plain wordsIn growth hormone-deficient men, higher-dose MK‑677 increased IGF-I from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-I at higher dose
Study
n = 5
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 mg/day · oral · 4 daysAs given in this study (human).
Measurements
IGF-I change from baseline
79%
50 mg/day MK-677, geometric mean +/- intrasubject SE 9
IGF-I at baseline
84 micrograms/L
50 mg/day MK-677
IGF-I after treatment
150 micrograms/L
50 mg/day MK-677
p value for IGF-I at higher dose vs baseline
≤ 0.05 p
50 mg/day MK-677 vs baseline, after treatment
IGF-I baseline reported +/- uncertainty term
3 micrograms/L
50 mg/day MK-677, baseline
IGF-I after-treatment reported +/- uncertainty term
6 micrograms/L
50 mg/day MK-677, after treatment
Source sentences
Summary
Following treatment with 50 mg MK-677, IGF-I concentrations increased 79 +/- 9% (84 +/- 3 to 150 +/- 6 micrograms/L, P < or = 0.05 vs. baseline)
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938607
15HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 at 50 mg increased mean GH by 82 +/- 29% from baseline.
In plain wordsIn growth hormone-deficient men, higher-dose MK‑677 increased mean growth hormone from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseMean GH at higher dose
Study
n = 5
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 mg/day · oral · 4 daysAs given in this study (human).
Measurements
24 h mean GH change from baseline
82%
50 mg/day MK-677, geometric mean +/- intrasubject SE 29
24 h mean GH at baseline
0.21 microgram/L
50 mg/day MK-677
24 h mean GH after treatment
0.39 microgram/L
50 mg/day MK-677
p value for Mean GH at higher dose vs baseline
≤ 0.05 p
50 mg/day MK-677 vs baseline, after treatment
24 h mean GH baseline reported +/- uncertainty term
0.02 microgram/L
50 mg/day MK-677, baseline
24 h mean GH after-treatment reported +/- uncertainty term
0.04 microgram/L
50 mg/day MK-677, after treatment
Source sentences
Summary
and 24-h mean GH concentrations increased 82 +/- 29% (0.21 +/- 0.02 to 0.39 +/- 0.04 microgram/L, P < or = 0.05 vs. baseline), respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Report a problemFND-0932938608
16HumanNon-randomized trialEfficacy outcome
In GH-deficient men, MK‑677 at 50 mg increased IGF binding protein-3 from baseline.
In plain wordsIn growth hormone-deficient men, higher-dose MK‑677 increased IGF binding protein-3 from baseline.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF binding protein-3 at higher dose
Study
n = 5
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 mg/day · oral · 4 daysAs given in this study (human).
Measurements
IGFBP-3 at baseline
1.7 micrograms/L
50 mg/day MK-677
IGFBP-3 after treatment
2.2 micrograms/L
50 mg/day MK-677
p value for IGF binding protein-3 at higher dose vs baseline
≤ 0.05 p
50 mg/day MK-677 vs baseline, after treatment
IGFBP-3 baseline reported +/- uncertainty term
0.1 micrograms/L
50 mg/day MK-677, baseline
IGFBP-3 after-treatment reported +/- uncertainty term
0.2 micrograms/L
50 mg/day MK-677, after treatment
Source sentences
Summary
Serum IGF binding protein-3 concentrations increased with both 10 mg (1.2 +/- 0.1 to 1.7 +/- 0.1 micrograms/L, P < or = 0.05) and 50 mg MK-677 (1.7 +/- 0.1 to 2.2 +/- 0.2 micrograms/L, P < or = 0.05).
5 context sentences(design, population, supporting numbers)
Summary · context
Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2.
Summary · context
Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively.
Summary · context
Blood was collected every 20 min for 24 h before treatment and at the end of each period for GH measurement using an ultrasensitive assay.
Summary · context
we studied nine severely GH-deficient men
Summary · context
In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days.
Report a problemFND-0932938610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 2
14 Oct 2026, 01:46 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

Summary

Results from this study16

Version history

Subjects

Publication types

MeSH terms